Positive opinion supports expanded treatment access
Positive opinion supports expanded treatment access
Still time to secure your place at MAD World Summit 2026
Regulatory progress supports accelerated approval pathway
Positive phase 2 data supports ETD001 designation
RNA therapy reduces triglycerides and pancreatitis risk
New maintenance option after first-line chemotherapy
First participant enters treatment extension phase
£8m initiative to support cancer discovery
Phase 2 data expected during 2027
Recommendation expands options for bladder cancer
Phase 1 study targets hard-to-treat patients
Agreement covers IBD drug candidate
Philanthropy initiative targets treatment innovation
Agreement covers two FDA-approved immunology treatments
Axcellant appointed global CRO for multinational trial